medigraphic.com
ISSN 0016-3813 (Print)

2015, Number 2

<< Back Next >>

Gac Med Mex 2015; 151 (2)

Prevalence, associated factors and phenomenology of psychosis in patients with Parkinson’s disease (PD)

Rodríguez-Violante M, Velázquez-Osuna S, Cervantes-Arriaga A, Corona-Vázquez T, de la Fuente-Sandoval C

Language: Spanish
References: 39
Page: 169-175
PDF size: 109.54 Kb.


ABSTRACT

Introduction: Psychosis associated with Parkinson’s disease is a major neuropsychiatric complication; it has been reported that 60% of patients will develop psychosis during the disease evolution. Its pathophysiology is multifactorial and clinically psychotic phenomena include minor hallucinations and confusional states. Material and Methods: We performed a cross-sectional study in patients with Parkinson’s disease from a tertiary hospital using a thoughtful neurological and neuropsychiatric evaluation along with specific scales for non-motor symptoms, depression, cognition, and presence and severity of psychotic symptoms and hallucinations. Results: We included a total of 236 patients with Parkinson’s disease, of which 33 (13.9%) patients met the criteria for psychosis at the time of the evaluation. Visual hallucinations were the most common symptom. Age (p = 0.004), age at onset of the disease (p = 0.007) and its duration (p = 0.004), use of levodopa (p = 0.02), and use of amantadine (p = 0.004) were the main factors associated with the presence of psychosis. Conclusion: Psychosis in Parkinson’s disease is a relatively common manifestation and is mainly associated with clinical and demographic factors. Early recognition will optimize management and improve the quality of life of patients and their caregivers.


REFERENCES

  1. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol. 2010;289(1-2):12-7.

  2. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population- based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996-1001.

  3. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-44.

  4. Mack J, Rabins P, Anderson K, et al. Prevalence of Psychotic Symptoms in a Community-Based Parkinson’s Disease Sample. Am J Geriatr Psychiatry. 2012;20(2):123-32.

  5. Stella F, Banzato CEM, Quagliato EMAB, Viana MA, Christofoletti G. Psychopathological features in patients with Parkinson’s disease and related caregivers’ burden. Int J Geriatr Psychiatry. 2009;24(10):1158-65.

  6. McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia. Parkinsonism Relat Disord. 2008;14(1):37-42.

  7. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005;64(1):81-6.

  8. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord. 2007;22(7):938-45.

  9. Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: Common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858-63.

  10. Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism Relat Disord. 2013;19(8):725-31.

  11. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605-10.

  12. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665-82.

  13. Goldman J. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacotherap. 2011;12(13):2009-24.

  14. MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA. Parkinson’s disease duration determines effect of dopaminergic therapy on ventral striatum function. Mov Disord. 2013; 28(2):153-60.

  15. Harding AJ. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain. 2002;125(Pt 11):2431-45.

  16. Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson’s disease: Clues to separate origins. J Neurol Sci. 2006;248(1-2):143-50.

  17. Diederich N, Goetz C, Stebbins G. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005;20(2): 130-40.

  18. Morgante L, Colosimo C, Antonini A, et al. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83(1):76-82.

  19. Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson’s disease: results from a large prospective cohort study. Mov Disord. 2013;28(6):755-62.

  20. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061-8.

  21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-4.

  22. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, Corona T. Cálculo de unidades de equivalencia de levodopa en enfermedad de Parkinson. Arch Neurocien (Mex). 2009;14:116-9.

  23. Hoehn MM, Yahr MD. Parkinsonism : onset, progression, and mortality. Neurology. 1967;17(5):427-42.

  24. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-8.

  25. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society- sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.

  26. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.

  27. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry. 1983;40(7):812.

  28. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;(7):59-67.

  29. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS. The Positive and Negative Syndrome Scale--Spanish adaptation. J Nerv Ment Dis. 1990;178(8):510-7.

  30. Wada-Isoe K, Ohta K, Imamura K, et al. Assessment of hallucinations in Parkinson’s disease using a novel scale. Acta Neurol Scand. 2008;117(1):35-40.

  31. Papapetropoulos S, Katzen H, Schrag A, et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol. 2008;8:21.

  32. Fénelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-6.

  33. Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858-63.

  34. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease Prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733-45.

  35. Rodríguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, Corona T. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson’s disease. Neurologia. 2011;26(6):319-24.

  36. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175-82.

  37. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-95.

  38. The French Clozapine Study Group. Clozapine in drug - induced psychosis in Parkinson’s disease. Lancet. 1999;353(9169):2041-2.

  39. Mohr E, Mendis T, Hildebrand K, Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord. 2000;15(6):1230-7.




2020     |     www.medigraphic.com